Free minds from bleeding damage
BLEEDnFIRE Therapeutics develops first-in-class siRNA therapeutics targeting Protein S across major bleeding disorders.
Proposition
BLEEDnFIRE is a Switzerland-based biotechnology company developing RNA-based therapies for bleeding disorders. Our lead program, BnF-001, is a GalNAc-conjugated siRNA designed to selectively reduce hepatic Protein S and restore thrombin generation through controlled rebalancing of coagulation.
This approach is being developed across hemophilia A, von Willebrand disease, and Glanzmann thrombasthenia, with the potential to address both bleeding burden and treatment burden through a single mechanism.
A new approach to bleeding disorders
Precision modulation through siRNA
One mechanism across multiple indications and joint bleeding
Potential for infrequent subcutaneous dosing
BnF-001
BnF-001 is the only siRNA therapeutic targeting Protein S known to us in development for major bleeding disorders. Preclinical and translational data support its potential to restore thrombin generation across multiple disease settings, with additional evidence suggesting benefit on joint and bone preservation.
Built on science. Designed for translation.
BLEEDnFIRE brings together expertise in hemostasis, RNA therapeutics, drug development, CMC, strategy, commercialization and company building to advance a differentiated therapeutic platform from discovery toward the clinic.